CNTN
Tharimmune, Inc.
NASDAQ · USHealthcareBiotechnology
$2.05-10.87%
Price as of Jul 20, 2026
CNTN growth
Tharimmune, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- +95.4%
- Free cash flow
- -95.8%
- Operating cash flow
- -95.8%
Forward estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- -61.7%
- Net income
- —
- EPS
- +88.1%
- Free cash flow
- -47.9%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.